Evidence map›Paper›PMID 41085687›Full record

ArticleAnnals of hematology2025

Von Willebrand factor and JAK2V617F variant allele frequency predict thrombosis and bleeding in patients with myeloproliferative neoplasms.

Ayala Gat, Romi Kazoom, Inbal Shapira, Ela Shai, Batia Roth Jelinek, Noa Buchman, Yosef Kalish, Ariela Arad, Eran Zimran

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ayala GatFaculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Romi KazoomFaculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Inbal ShapiraFaculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Ela ShaiDepartment of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Batia Roth JelinekDepartment of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Noa BuchmanDepartment of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Yosef KalishDepartment of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Ariela Arad *Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
Eran Zimran *Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. eran.zimran@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombosis is a major cause of morbidity and mortality in patients with myeloproliferative neoplasms (MPN), while bleeding is also common. Current thrombosis and bleeding risk stratification strategies are limited, creating a need for identification of novel risk factors to better predict these complications. We performed laboratory coagulation testing and driver mutation profiling from peripheral blood of patients with MPN. Patients' history of comorbidities, hematological variables and thrombosis and/or bleeding events were collected retrospectively at the time of testing. Patients were then followed for a median of 3.3 years for incident events. 198 patients were included in the study. Thrombotic events occurred in 41% of the patients. Age, cardiovascular comorbidities and constitutional symptoms were significantly associated with thrombosis, as well as elevated von Willebrand Factor (vWF): Antigen, vWF: Activity and factor VIII levels. Elevated vWF: Antigen levels remained independent in multivariate analysis and were predictive of incident thrombosis. Bleeding events occurred in 26% of the patients. vWF: Activity ≤ 30%, vWF: Activity-to-antigen ratio of ≤ 0.7, a platelet count of ≥ 500*10

Indexed as

Gene FrequencyHemorrhageJanus Kinase 2Mutation, MissenseMyeloproliferative DisordersThrombosisvon Willebrand FactorAdultAgedAged, 80 and overAmino Acid SubstitutionFemaleHumansMaleMiddle AgedRetrospective StudiesJAK2 protein, humanJanus Kinase 2von Willebrand FactorBleedingJAK2V617F variant allele frequencyMyeloproliferative neoplasmsThrombosisVon willebrand factor

Identifiers

PMID41085687
PMCPMC12619820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.